Personalis, Inc., a Menlo Park, California-based provider of advanced medical exome and genome sequencing and interpretation services, closed a $22m Series B financing.
The round was led by Abingworth, with participation from existing investors Lightspeed Venture Partners and Mohr Davidow Ventures and new investors Wellington Shields & Co.
The company intends to use the funds to expand its product offerings, scale operations, and expand the commercial team.
Led by CEO John West, Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human genomes. The company serves researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Its laboratory achieved CLIA validation in January 2013. Commercially, Personalis now has direct sales representatives and a field based support team for North America, has established a UK subsidiary and hired the initial European sales team.